โ† Live radar Archive

๐Ÿ“ก RADAR REPORT

Monday, 16 November 2026 ยท data as of 2026-11-16 20:25 UTC
ACTIVE TRIALS8,737
P3 READOUTS ยท 14D25
P3 READOUTS ยท 30D127
CHANGES ยท 7D37
LATE >6 MONTHS46%
Get the Radar Report by email โ€” a weekly digest, free.

Phase 3 readouts due ยท next 14 days

25 trials with an exact primary-completion date in the next two weeks (127 in the next 30 days).
DateTrialSponsorAreaNvs. original plan
2026-11-18 est.POETYK SjS-1Bristol-Myers Squibb $BMYImmuno774+0.0 mo
2026-11-18 est.Drugs-SNPsMedicine Invention Design, IncOncology600+30.0 mo
2026-11-20 est.PembrolizumabMerck Sharp & Dohme LLC $MRKOncology990+17.1 mo
2026-11-21 est.Cabergoline tabletsChangchun GeneScience Pharmaceutical Co., Ltd.Cardio-Met382+14.0 mo
2026-11-23 est.Investigational varicella vaccineGlaxoSmithKline $GSKInfectious750+4.4 mo
2026-11-23 est.dTpaGlaxoSmithKline $GSKInfectious102โ€”
2026-11-24 est.KarXTKaruna Therapeutics, Inc., a Bristol Myers Squibb companyNeuro406+0.8 mo
2026-11-24 est.AvelumabEMD Serono Research & Development Institute, Inc. $MRK.DEOncology205+33.9 mo
2026-11-24 est.177Lu-DOTATATE injectionHTA Co., Ltd.Other184+0.0 mo
2026-11-25 est.ICP-332 TabletsBeijing InnoCare Pharma Tech Co., Ltd.Immuno552+0.0 mo
2026-11-25 est.rilzabrutinibSanofi $SNYCardio-Met3-0.2 mo
2026-11-26 est.RUBYTesaro, Inc.Oncology785+60.0 mo
2026-11-26 est.MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd.Cardio-Met424+0.0 mo
2026-11-28 est.Yellow fever vaccine (live)Sanofi $SNYInfectious2440+3.7 mo
2026-11-29 est.RimegepantPfizer $PFENeuro723+5.9 mo
2026-11-30 est.D-0502InventisBio Co., LtdOncology640+0.0 mo
2026-11-30 est.AtezolizumabHoffmann-La Roche $ROG.SWOncology382-8.1 mo
2026-11-30 est.Drug:WD-890Zhejiang Wenda Pharma Technology LTD.Immuno375โ€”
2026-11-30 est.A166Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. $6990.HKOncology365+12.0 mo
2026-11-30 est.SL1002Saol Therapeutics IncNeuro150+0.0 mo
2026-11-30 est.Neuroncell-EXCytopeutics Sdn. Bhd.Cardio-Met80+21.7 mo
2026-11-30 est.GS1191-0445 injectionGritgen Therapeutics Co., Ltd.Rare50+0.0 mo
2026-11-30 est.TS-172 20~60 mg/dayTaisho Pharmaceutical Co., Ltd.Other34โ€”
2026-11-30 est.LeniolisibPharming Technologies B.V.Other15+29.7 mo
2026-11-30 est.AVTX-803 (L-Fucose)AUG TherapeuticsOther4+47.0 mo

Registry changes ยท last 7 days

Phase 3 / 2-3 trials whose ClinicalTrials.gov record changed (status, readout date, enrollment, sites), plus stops and results posted.
TrialSponsorChange
AB-3028Arsenal Biosciences, Inc.Active, not recruiting โ†’ Terminated
ICM ADX-2191 injectionAldeyra Therapeutics, Inc.readout 2026-12 โ†’ 2029-12 (+36.0 mo)
DuraSTARGlaxoSmithKline $GSKreadout 2029-12-12 โ†’ 2030-03-13 (+3.0 mo)
WILL-EMIHoffmann-La Roche $ROG.SWreadout 2027-04-30 โ†’ 2027-10-06 (+5.2 mo)
Citicoline eye drops 2%Omikron Italia S.r.l.readout 2026-04-01 โ†’ 2029-07-01 (+39.0 mo)
RASolute 303Revolution Medicines, Inc. $RVMDreadout 2028-06 โ†’ 2028-04 (-2.0 mo)
Sinovac rabies vaccineSinovac Biotech Co., Ltdreadout 2026-09-30 โ†’ 2026-07-15 (-2.5 mo)
ZasocitinibTakeda $TAKreadout 2033-01-24 โ†’ 2034-07-03 (+17.2 mo)
IPAX BrIGHTTelix Pharmaceuticals (Innovations) Pty Limitedreadout 2027-07 โ†’ 2028-07 (+12.0 mo)
LiraglutideNovo Nordisk A/S $NVOresults posted
DuraSTARGlaxoSmithKline $GSKenrollment 90 โ†’ 100
Citicoline eye drops 2%Omikron Italia S.r.l.enrollment 1000 โ†’ 873
ZasocitinibTakeda $TAKenrollment 110 โ†’ 210
KN3835Endo USA Inc., a Keenova Therapeutics CompanyNot yet recruiting โ†’ Recruiting
Citicoline eye drops 2%Omikron Italia S.r.l.Recruiting โ†’ Active, not recruiting
MOUNTAINEER-03Seagen, a wholly owned subsidiary of Pfizer $PFERecruiting โ†’ Active, not recruiting
Sinovac rabies vaccineSinovac Biotech Co., LtdNot yet recruiting โ†’ Active, not recruiting
ZG005 for InjectionSuzhou Zelgen Biopharmaceuticals Co.,LtdNot yet recruiting โ†’ Recruiting
VK2735Viking Therapeutics, Inc. $VKTXNot yet recruiting โ†’ Recruiting
VK2735 OralViking Therapeutics, Inc. $VKTXNot yet recruiting โ†’ Recruiting
DLBS1442Dexa Medica Groupnewly registered
FenebrutinibHoffmann-La Roche $ROG.SWnewly registered
PINNACLE-MINovartis Pharmaceuticals $NVSnewly registered
OlpasiranAmgen $AMGNsites 252 โ†’ 261
TeLuRide-008Eikon Therapeuticssites 42 โ†’ 52
KN3835Endo USA Inc., a Keenova Therapeutics Companysites 0 โ†’ 4
RAINFOL-04Genmab $GMABsites 34 โ†’ 69
DuraSTARGlaxoSmithKline $GSKsites 0 โ†’ 1
PERSISTCRSwNP2GlaxoSmithKline $GSKsites 4 โ†’ 7
ZUPREME-5Hoffmann-La Roche $ROG.SWsites 3 โ†’ 11

Delay Index

Across 5,352 active trials registered more than a year ago, 46% have moved their readout date by more than 6 months since first registration.

Most often late

SponsorTrials>6 mo late
Acerta Pharma BV1191%
Ionis Pharmaceuticals, Inc. $IONS1283%
Taiho Oncology, Inc.1070%
Allist Pharmaceuticals, Inc.1267%
Seagen, a wholly owned subsidiary of Pfizer $PFE1267%

Most on time

SponsorTrialsOn time ยฑ1 mo
Qilu Pharmaceutical Co., Ltd.3388%
Ono Pharmaceutical Co., Ltd. $4528.T1385%
Biocad1283%
Shanghai JMT-Bio Inc.1283%
Dizal Pharmaceuticals1080%

FDA this week

New NDA/BLA approvals and Class I drug recalls (last 7 days), and manufacturing (CGMP) or trial-conduct warning letters (last 14 days).
TypeWhatCompanyDate
โœ“ ApprovalOXDERYS (doxorubicin hydrochloride)AVYXA HOLDINGS2026-11-09
โœ“ ApprovalNDA221291BAYER HEALTHCARE $BAYN.DE2026-11-09
โœ“ ApprovalMULTIBIC (multibic)FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC2026-11-09
โœ‰ Warning letterRequest for Records/CGMP/API/AdulteratedNanjing Hanxin Pharmaceutical Technology Co. Ltd.2026-11-03
โœ‰ Warning letterCGMP/Finished Pharmaceuticals/AdulteratedUSV Private Limited2026-11-02

New Phase 3 trials ยท last 7 days

30 Phase 3 / 2-3 trials were first posted on ClinicalTrials.gov.
TrialSponsorAreaN
PINNACLE-MINovartis Pharmaceuticals $NVSCardio-Met10000
FrexalimabSanofi $SNYNeuro2500
FenebrutinibHoffmann-La Roche $ROG.SWNeuro1800
AMBITION 3Novo Nordisk A/S $NVOCardio-Met1200
AMBITION4Novo Nordisk A/S $NVOCardio-Met1060
BerobenatidePfizer $PFECardio-Met900
RC118(Dose 1) plus RC148(Dose 1)RemeGen Co., Ltd.Oncology680
SYS6010CSPC Megalith Biopharmaceutical Co.,Ltd. $1093.HKOncology585
ABBV-722AbbVie $ABBVImmuno580
AMBITION 2Novo Nordisk A/S $NVOCardio-Met450
SYS6010 combined with EnlonstobartCSPC Megalith Biopharmaceutical Co.,Ltd. $1093.HKOncology424
QLS5132Qilu Pharmaceutical Co., Ltd.Oncology420
NP-101Novatek PharmaceuticalsOncology381
TLX101-PxTelix Pharmaceuticals (Innovations) Pty LimitedOncology381
RC28-ERemeGen Co., Ltd.Cardio-Met350

Post text

Ready to paste on LinkedIn or X.
๐Ÿ“ก TrialSonar Radar Report ยท 16 Nov 2026

โฑ 25 Phase 3 readouts due in the next 14 days (127 in 30):
โ€ข 2026-11-18 โ€” POETYK SjS-1 (Bristol-Myers Squibb $BMY, Immuno)
โ€ข 2026-11-18 โ€” Drugs-SNPs (Medicine Invention Design, Inc, Oncology)
โ€ข 2026-11-20 โ€” Pembrolizumab (Merck Sharp & Dohme LLC $MRK, Oncology)
โ€ข 2026-11-21 โ€” Cabergoline tablets (Changchun GeneScience Pharmaceutical Co., Ltd., Cardio-Met)
โ€ข 2026-11-23 โ€” Investigational varicella vaccine (GlaxoSmithKline $GSK, Infectious)

๐Ÿ” Registry changes this week:
โ€ข AB-3028 (Arsenal Biosciences, Inc.): Active, not recruiting โ†’ Terminated
โ€ข ICM ADX-2191 injection (Aldeyra Therapeutics, Inc.): readout 2026-12 โ†’ 2029-12 (+36.0 mo)
โ€ข DuraSTAR (GlaxoSmithKline $GSK): readout 2029-12-12 โ†’ 2030-03-13 (+3.0 mo)
โ€ข WILL-EMI (Hoffmann-La Roche $ROG.SW): readout 2027-04-30 โ†’ 2027-10-06 (+5.2 mo)

๐Ÿ“‰ Delay Index: 46% of active trials (registered >1 yr ago) have pushed their readout >6 months.
Most often late: Acerta Pharma BV 91%, Ionis Pharmaceuticals, Inc. 83%, Taiho Oncology, Inc. 70%

โš• FDA: OXDERYS approved (AVYXA HOLDINGS); NDA221291 approved (BAYER HEALTHCARE); MULTIBIC approved (FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC); warning letter to Nanjing Hanxin Pharmaceutical Technology Co. Ltd.; warning letter to USV Private Limited

Full report & live map: https://trialsonar.netlify.app/report/
Data: ClinicalTrials.gov, openFDA, fda.gov. Not investment advice.

Sources: ClinicalTrials.gov (U.S. NLM), openFDA and fda.gov warning letters. Primary completion dates are sponsor-reported and often estimates; readout = last primary-endpoint data collected, not results publication. For information only โ€” not investment or medical advice. Disclaimer